Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells

Authors: Yi Zhang, Fu-qiang Chen, Ye-hong Sun, Shu-yan Zhou, Ti-yuan Li, Rui Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Background

DNA methylation has been widely used in classification, early diagnosis, therapy and prediction of metastasis as well as recurrence of cervical cancer. DNMT methyltransferase 1 (DNMT1), which plays a significant role in maintaining DNA methylation status and regulating the expression of tumor suppressor genes. The aim of this research was to investigate the relationship between DNMT1 and abnormal methylation of tumor suppressor genes and malignant phenotype in cervical cancer.

Methods

Levels of DNMT1 mRNA and protein were detected using qPCR and Western blot, respectively. Cell proliferation was analyzed by MTT and apoptosis was performed by Annexin V-FITC/PI double staining flow cytometry, respectively. MeDIP-qPCR and qPCR were performed to measure demethylation status and mRNA re-expression level of 7 tumor-suppressor genes (CCNA1, CHFR, FHIT, PAX1, PTEN, SFRP4, TSLC1) in Hela and Siha cells after silencing DNMT1.

Results

The average expression levels of DNMT1 mRNA and protein in Hela and Siha cells were decreased significantly compared with control group. The flow cytometry and MTT results showed that Hela and Siha cells apoptosis rates and cell viabilities were 19.4 ± 2.90%, 25.7 ± 3.92% as well as 86.7 ± 3.12%, 84.16 ± 2.67% respectively 48 h after transfection (P < 0.01). Furthermore, the promoter methylation of five tumor suppressor genes was decreased with the increased mRNA expression after silencing DNMT1, whereas there were no significant changes in PTEN and FHIT genes in Hela cells, and CHFR and FHIT genes in Siha cells.

Conclusions

Our experimental results demonstrate that methylation status of DNMT1 can influence several important tumor suppressor genes activity in cervical tumorigenesis and may have the potential to become an effective target for treatment of cervical cancer.
Appendix
Available only for authorised users
Literature
1.
Ongenaert M, Wisman GB, Volders HH, Koning AJ, Zee AG, van Criekinge W, Schuuring E: Discovery of DNA methylation markers in cervical cancer using relaxation ranking. BMC Med Genomics. 2008, 1: 57-10.1186/1755-8794-1-57.PubMedCentralCrossRefPubMed
2.
Szyf M: The role of DNA methyltransferase 1 in growth control. Front Biosci. 2001, 6: D599-609. 10.2741/szyf.CrossRefPubMed
3.
Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S, Hirohashi S: DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 2006, 27 (6): 1160-1168. 10.1093/carcin/bgi361.CrossRefPubMed
4.
Sowinska A, Jagodzinski PP: RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12 expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines. Cancer letters. 2007, 255 (1): 153-159. 10.1016/j.canlet.2007.04.004.CrossRefPubMed
5.
Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002, 416 (6880): 552-556. 10.1038/416552a.CrossRefPubMed
6.
Robert SM, Beaulieu Normand, Gauthier France: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nature genetics. 2002, 33 (9): 61-65.CrossRefPubMed
7.
Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD: RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer research. 2004, 64 (9): 3137-3143. 10.1158/0008-5472.CAN-03-3046.CrossRefPubMed
8.
Leu YW, Rahmatpanah F, Shi H, Wei SH, Liu JC, Yan PS, Huang TH: Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer research. 2003, 63 (19): 6110-6115.PubMed
9.
Ting AH, Jair KW, Suzuki H, Yen RW, Baylin SB, Schuebel KE: CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nature genetics. 2004, 36 (6): 582-584. 10.1038/ng1365.CrossRefPubMed
10.
Ye C, Shrubsole MJ, Cai Q, Ness R, Grady WM, Smalley W, Cai H, Washington K, Zheng W: Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncology reports. 2006, 16 (2): 429-435.PubMed
11.
Hsieh SM, Maguire DJ, Lintell NA, McCabe M, Griffiths LR: PTEN and NDUFB8 aberrations in cervical cancer tissue. Advances in experimental medicine and biology. 2007, 599: 31-36. 10.1007/978-0-387-71764-7_5.CrossRefPubMed
12.
Qi M, Anderson AE, Chen DZ, Sun S, Auborn KJ, et al: Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Molecular medicine. 2005, Cambridge, Mass, 11 (1-12): 59-63.
13.
Wu Y, Meng L, Wang H, Xu Q, Wang S, Wu S, Xi L, Zhao Y, Zhou J, Xu G, et al: Regulation of DNA methylation on the expression of the FHIT gene contributes to cervical carcinoma cell tumorigenesis. Oncology reports. 2006, 16 (3): 625-629.PubMed
14.
Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, Iwata T, Hirasawa A, Fujii T, Susumu N, et al: Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. International journal of oncology. 2007, 31 (4): 713-720.PubMed
15.
Cheung HW, Ching YP, Nicholls JM, Ling MT, Wong YC, Hui N, Cheung A, Tsao SW, Wang Q, Yeun PW, et al: Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Molecular carcinogenesis. 2005, 43 (4): 237-245. 10.1002/mc.20106.CrossRefPubMed
16.
Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, Chu TY, Lai HC, Lin YW: Promoter methylation of SFRPs gene family in cervical cancer. Gynecologic oncology. 2009, 112 (2): 301-306. 10.1016/j.ygyno.2008.10.004.CrossRefPubMed
17.
Kitkumthorn N, Yanatatsanajit P, Kiatpongsan S, Phokaew C, Triratanachat S, Trivijitsilp P, Termrungruanglert W, Tresukosol D, Niruthisard S, Mutirangura A: Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer. BMC cancer. 2006, 6: 55-10.1186/1471-2407-6-55.PubMedCentralCrossRefPubMed
18.
Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, et al: Identification of novel DNA methylation markers in cervical cancer. International journal of cancer. 2008, 123 (1): 161-167. 10.1002/ijc.23519.CrossRef
19.
Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, Snijders PJ: TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. Journal of the National Cancer Institute. 2004, 96 (4): 294-305. 10.1093/jnci/djh031.CrossRefPubMed
Metadata
Title
Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells
Authors
Yi Zhang
Fu-qiang Chen
Ye-hong Sun
Shu-yan Zhou
Ti-yuan Li
Rui Chen
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-98

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue

Research

More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells

Research

The research on the immuno-modulatory defect of Mesenchymal Stem Cell from Chronic Myeloid Leukemia patients

Research

Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity

Research

Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer

Research

RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study

Research

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits